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HEALTH CARE RESOURCE UTILIZATION (HRU) AND DIRECT MEDICAL
EXPENDITURES (DME) FOR ADULT WOMEN WITH ANXIETY DISORDERS (AD) IN
THE UNITED STATES IN 2006 USING MEDICAL EXPENDITURES PANEL SURVEY
(MEPS)
Kavati A, Rappaport H
University of Louisiana at Monroe, Monroe, LA, USA
OBJECTIVES: Estimate HRU and DME for adult women with AD.METHODS: A ret-
rospective cross-sectional case-control design using 2006 MEPS. Females  17
years who reported AD were selected. A control group was created using propen-
sity score matching. The data was fitted to poisson (P), negative binomial (NB),
zero-inflated poisson (ZIP), and zero-inflated negative binomial (ZINB) models. A
plot of residuals was examined and the plot closest to zero was selected as the best
fitting model. To calculate the HRU attributable to AD, the unadjusted mean num-
ber of visits for those without AD was multiplied by the regression coefficient for
AD from the multivariate regression minus the unadjusted mean number of visits
for those without AD. To estimate DME, a generalized linear model (GLM) was
estimated with a Park’s test to select the appropriate variance function after which
the incremental expenditurewas calculated by themethod of recycled predictions.
All analyses incorporated the MEPS sampling and variance adjustment weights to
ensure nationally representative sample. All the component expenditures were
summed and multiplied by the number of females who reported AD in 2006 to get
the national estimate of direct medical expenditures. RESULTS: The annual num-
ber of inpatient, emergency room, outpatient, and office based visits attributable to
ADwas 0.03, 0.07, 0.34, AND4.3 respectively. Therewere 0.05 homehealth days and
8.47 prescriptions including refills obtained by adult women with AD. The esti-
mated national annual direct COI associated with AD among adult women was
$26.52 billion. This was calculated bymultiplying the per-person total incremental
medical expenditure associated with AD among female adults ($2,143.16) with the
prevalence of AD (12,374,189). CONCLUSIONS: Inpatient expenditures accounted
for the largest proportion of DME followed by office based and prescription expen-
ditures. Adult women with AD have a significant societal burden.
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ANTIDEPRESSANT PERSISTENCE AND ASSOCIATED HEALTH CARE
EXPENDITURES IN CHILDREN WITH DEPRESSION
Karkare S1, Aparasu RR2, Chen H2, Rajan SS2
1Center for Medical Technology and Policy, Baltimore, MD, USA, 2University of Houston, Houston,
TX, USA
OBJECTIVES: The objectives of the study were to examine persistence and factors
associated with persistence to antidepressant medications in depressed children
and adolescents and to evaluate health care expenditures across persistent pa-
tients and non-persistent patients. METHODS: Medical Expenditure Panel Survey
(MEPS) data from the years 2002-2007 were used for the analysis. The study sample
consisted of depressed children and adolescents taking an antidepressant. Multi-
ple logistic regression analysis was conducted to examine factors associated with
persistence, after controlling for various independent variables like the predispos-
ing, enabling and need factors chosen on the basis of Anderson Behavioral Model,
and controls for year and timeframe. Linear regression models, containing log of
prescription drug expenditures and ambulatory expenditures as the dependent
variables, were used to evaluate the expenditures. Unweighted statistical analysis
was performed due to small sample cell size. RESULTS: Analytical sample con-
sisted of 281 children and adolescents using antidepressants. Approximately 53%
of the children and adolescents initiated on the antidepressant therapy were not
persistent. Social limitation was found to be a significant predictor increasing per-
sistence. Switching was prevalent in 16% of the children and adolescents. Analysis
of expenditures revealed that being persistent led to a 2.5 times increase in the
prescription drug expenditures, with no impact on ambulatory care expenditures.
CONCLUSIONS: Over half of the patients on antidepressant therapy were not persis-
tent. Although persistence of antidepressant therapy did not translate into reduction
in ambulatory expenditures, it may play a role in clinical and humanistic outcomes.
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RETROSPECTIVE ANALYSIS OF THE IMPACT OF PERSISTENCE ON HEALTH CARE
CHARGES AMONG OPIOID-DEPENDENT PATIENTS TREATED WITH
BUPRENORPHINE/NALOXONE USING AN INSURANCE DATABASE IN THE
UNITED STATES
Zah V1, Aballea S2, Guelfucci F3, Clay E3, Baxter T4
1ISPOR Serbia, Beograd, Serbia and Montenegro, 2Creativ Ceutical, Paris, Ile de France, France,
3Creativ Research, Paris, France, 4Reckitt Benckiser Pharmaceuticals Inc, Richmond, VA, USA
OBJECTIVES: Buprenorphine/naloxone (Suboxone®, Reckitt-Benckiser) is recom-
mended for treating opiate addiction. Clinical guidelines do not specify the mini-
mum duration of treatment required to achieve long-term remission. This study
evaluated the impact of persistence on resource utilisation andhealthcare charges.
METHODS: This retrospective study used a US insurance claims database. It in-
cluded patients with a BUP/NAL claim, not previously treated with buprenorphine,
with at least one repeat claim after 30 days. Discontinuation was defined as ab-
sence of BUP/NAL claim for 90 days. Healthcare charges over 12 months were
compared between persistent and non-persistent patients, adjusting on baseline
characteristics (demographics, comorbidities, treatment, and resource utilisation
before index date). Charges before and after discontinuation were compared using
generalized linear models with repeated observations. RESULTS: Of 6868 patients
with an incident claim of BUP/NAL, 42.4% appeared to be short-term users and
were excluded. Among the remaining 3955 patients, 1287 were followed for at least
one year. The Kaplan-Meier estimate of the probability of continuing treatment
over 12 months was 61.2%. No significant predictors of discontinuation were iden-
tified except age and initial dose. The 12-month persistent cohort had lower mean
total charges compared to non-persistent patients ($22,033 vs. $30,518; p0.0012
adjusting on baseline characteristics). Among non-persistent patients, total
charges reached a maximum during the first trimester following discontinuation
(63% compared to period from 6 to 4 months before discontinuation, p0.0001),
and were non-significantly higher in the second trimester after discontinuation
compared to before discontinuation. Main drivers of excess charges were hospital-
ization and outpatient visits. CONCLUSIONS: Among long-term users of BUP/NAL,
a substantial proportion discontinued treatment within 12 months. This analysis
showed that non-persistence was associated with higher charges and evidence
was consistent with a causal relationship between discontinuation and increased
charges. However, identifying causes of discontinuation and means to improve
persistence using claims data is challenging.
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UTILIZATION, PRICE AND SPENDING TRENDS FOR
SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS IN THE UNITED STATES
MEDICAID PROGRAM: 1991-2009
Isla A, Guo JJ, Lin AC, Kelton CM, Heaton PC
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: Serotonin–norepinephrine reuptake inhibitors (SNRIs), comprising
arelatively new class of antidepressant drugs, have multiple approved indication-
ssuch as major depressive disorder and fibromyalgia. The objectives of this study-
were to (1) describe the trends in drug utilization, spending, and price for the
U.S.Medicaid program and (2) analyze the change in SNRI market share in the
marketfor all antidepressants, including as well selective serotonin reuptake in-
hibitors andtricyclic antidepressants.METHODS:A retrospective, descriptive anal-
ysis was performed using the national Medicaid pharmacy claims database, which
has information on outpatient prescription claims. Quarterly prescription counts
and reimbursement amounts were calculated for each of the SNRIs (branded or
generic) reimbursed by Medicaid from 1994 quarter 1 through 2009 quarter 4. Av-
erage per-prescriptions pending (implicit price) was found by dividing reimburse-
ment by the number of prescriptions. RESULTS: Until 2009, venlafaxine was the
most prescribed SNRI at which time it was topped in utilization by duloxetine. In
2009, Medicaid spent $159million and $169million for venlafaxine and duloxetine,
respectively, for 1.00 and 1.07 million prescriptions. The price of venlafaxine has
increased over time (the price in 2009 was almost 3 times the price in 1998). Utili-
zation of the new extended-release formulation of venlafaxine (Effexor XR®) has
risen exponentially, and this new formulationwas 8 timesmore prescribed than its
predecessor in 2009. After 2008, two new SNRIs (Pristiq® and Savella®) were mar-
keted, but their market shares were still very small at the end of 2009. In total,
Medicaid spent $342 million for 2.20 million prescriptions for SNRIs in 2009. The
SNRIs as a class represented 20% of total Medicaid reimbursement for antidepres-
sants at the end of 2009. CONCLUSIONS: Increased utilization may be due to mul-
tiple approved indications. Very little price competition is observed between
brands or between brand andgeneric venlafaxine.
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PSYCHIATRIC MORBIDITY AND BURNOUT AMONG HOSPITAL PHYSICIANS AND
NURSES: ASSOCIATION WITH PERCEIVED JOB-RELATED FACTORS
Tabolli S, di Pietro C, Renzi C
IDI IRCCS, Rome, Italy
OBJECTIVES: To evaluate psychiatric morbidity and burnout among physicians
and nurses of a general hospital in central Italy, examining the association with
perceived job-related factors.METHODS:Anonymous questionnaires were distrib-
uted to all 323 hospital physicians and 609 nurses of a non-profit health organisa-
tion in Rome, Italy. Standardised instruments were used to evaluate psychiatric
morbidity (General Health Questionnaire), burnout (Maslach Burnout Inventory)
andperceived job-related factors. Stepwise logistic regressionwas used to examine
the association between job-related factors, psychiatric morbidity and burnout,
controlling for demographic factors. RESULTS: Questionnaires were returned by
155 physicians and 216 nurses (overall response rate 40%). Estimated prevalence of
psychiatric morbidity was 25% among physicians and 36.9% among nurses. Burn-
out on the emotional exhaustion scale affected 38.7% of physicians and 46.4% of
nurses. Personnel with emotional exhaustion was at higher risk of psychiatric
morbidity (p0.001). The likelihood of psychiatricmorbidity among physicianswas
increased by perceived insufficient recognition of personal commitments by the
unit’s head (OR4.21; 95%CI 1.2-15.1; p0.027), insufficient managerial ability of
the unit’s head (OR3.45; 95%CI 1.2-10.1; p0.023), unsatisfactory communication
(OR5.30;95%CI 1.6-17.6; p0.006). Among nurses, psychiatric morbidity was asso-
ciated with insufficient ability of the unit’s head to solve conflicts, insufficient
decisional power in relation to responsibilities, insufficient economic rewards and
career possibilities, working in surgery. Similar job-related factors were associated
also with emotional exhaustion. CONCLUSIONS: Psychiatric morbidity and burn-
out were relatively high, particularly among nurses. Specific job-related factors
were associated with psychiatric morbidity and burnout. Improving these aspects
is important for the well-being of hospital staff and the quality of patient care.
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PHARMACIST AND PHARMACY STAFF KNOWLEDGE AND ATTITUDES
TOWARDS SUICIDE AND SUICIDE PREVENTION AFTER A NATIONAL VA
TRAINING PROGRAM
Lavigne JE, King DA, Lu N, Knox KL, Kemp JE
U.S. Department of Veterans Health Affairs, Canandaigua, NY, USA
OBJECTIVES: To evaluate US Department of Veterans Affairs (VA) training in sui-
cide prevention on pharmacists’ and pharmacy staff’s knowledge of and attitudes
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toward suicide prevention.METHODS: Suicide prevention (SAVE or “guide”) train-
ingwas implemented nationwide starting in 2007. All employees that interact with
patientsmust take the 1-hour instructor-led class consisting of videos, worksheets
and discussion regarding suicide statistics, suicide risk factors, and the responsi-
bility of all VA employees to recognize suicide risk and to intervenewith patients in
distress, including taking an urgently distressed patient by the hand and walking
him from the outpatient pharmacy to the emergency room, for example. At the end
of training, employees completed surveys about attitudes and knowledge of sui-
cide and her role in prevention with Likert scales (range1 to 5). Descriptive sta-
tistics and generalized linear models (GLM) were used to assess differences in
pharmacy staff knowledge and attitudes before and after training and to compare
pharmacy staff to all employees. RESULTS: 7,431 employees from 251 VA Medical
Centers trained January 1- September 30, 2008, including 290 pharmacists, phar-
macy residents and pharmacy staff. At baseline, compared to all employees, phar-
macy staff reported lower levels of suicide knowledge (22% cf. 31%), comfort in
talking about suicide (43% cf. 59%), and being prepared to handle suicidal veterans
(10% cf. 28%). Pharmacists and pharmacy staff improved significantly on every
measure (p0.0001) by the end of training.We found no differences between phar-
macists and other pharmacy staff. After training when given the statement “I
completely agree that I am prepared to handle a suicidal veteran,” women and
those with additional suicide prevention training were most likely to agree while
men and older employees were least likely to do so. CONCLUSIONS: Pharmacists
and pharmacy staff may have greater baseline needs for training in suicide pre-
vention than other staff.
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UTILIZATION PATTERN OF PSYCHOTHERAPY AS AN ADJUNCT TO
PHARMACOTHERAPY AMONG AMBULATORY BIPOLAR DISORDER PATIENTS
Mehta S, Bhattacharya R, Aparasu RR
University of Houston, Houston, TX, USA
OBJECTIVES: Psychotherapy has been recommended to be used in conjunction
with pharmacotherapy for the treatment of bipolar disorder. This study examined
the prescribing patterns of the combination of psychotherapy and pharmacother-
apy to treat bipolar disorder in patients receiving outpatient care in the United
States.METHODS:Data from 2006–2007 National Ambulatory Medical Care Survey
(NAMCS) and the outpatient department of National Hospital Ambulatory Medical
Care Survey (NHAMCS) were combined to analyze treatment patterns for bipolar
disorder. Descriptive statistics was used to examine demographic as well as the
clinical characteristics of patients’ visits and the utilization pattern of psychother-
apy in combination with several psychotropic medications. RESULTS: Bipolar dis-
order was diagnosed in 6.09 million annualized outpatient visits in 2006-2007, rep-
resenting 0.29% of the overall visits. Most of the visits weremade by females (66%),
whites (91%) and non-Hispanics (94%). Psychiatric comorbidities such as anxiety
disorders, attention-deficit/ hyperactivity disorder and substance use disorder
were present in approximately 34% of the visits. The most frequently prescribed
psychotropicmedicationsweremood stabilizers (64%) followed by antidepressants
(54%) and atypical antipsychotics (44%). Psychotherapy along with a psychotropic
medication was prescribed in about 1.81 million visits (30%). The most prescribed
combinations were psychotherapy along with mood stabilizers in 1.46 million vis-
its (24.12%) and psychotherapy along with atypical antipsychotics in 1.19 million
visits (19.6%). CONCLUSIONS: Less than one-third of the patients with bipolar dis-
order were prescribed psychotherapy in combination with pharmacotherapy as
recommended for treatment of bipolar disorders. More research is needed to eval-
uate the reasons for possible sub-optimal use of psychotherapy in bipolar disor-
ders.
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PERSISTENCE OF STIMULANT TREATMENT IN CHILDREN AND ADOLESCENTS
WITH ATTENTION-DEFICIT HYPERACTIVITY DISORDER
Palli SR1, Aparasu RR2, Chen H2, Sherer JT2
1HealthCore, Inc., Wilmington, DE, USA, 2University of Houston, Houston, TX, USA
OBJECTIVES: To compare and identify the factors associated with persistence of
stimulant classes in children and adolescents with Attention-Deficit Hyperactivity
Disorder (ADHD).METHODS:A retrospective longitudinal cohort analysis was con-
ducted using the Medicaid Analytic eXtract data from 4 states - New York, Illinois,
Texas and California. ADHD patients, aged 6-18 years with at least one stimulant
prescription claim for a short-acting (SAS), intermediate-acting (IAS) or long-acting
stimulant (LAS) and one or more inpatient or outpatient claim involving a ADHD
diagnosis (ICD-9-CM code 314.xx) during the study period (January 2003 to Decem-
ber 2005) were selected. New stimulant users were defined as those with no previ-
ous stimulant drug prescription in the preceding 6 months. Additional criteria for
inclusion included 180 days of pre- and post-index continuous Medicaid eligibility
and no multiple index stimulant type claims. Persistence for the index stimulant
was measured by summing the number of days the patient remained on the index
stimulant therapy from the index prescription date with a maximum refill gap
between two consecutive index stimulant claims of 30 days. Stratified linear re-
gression modeling was used to determine the factors associated with persistence
for the three stimulant classes. RESULTS:Among the 63,362 ADHD patients (10,033
SAS, 5,061 IAS and 48,268 LAS users), LAS group had significantly longer mean and
median persistence (176 & 94 days), than the patients in SAS (102 & 60 days) or IAS
groups (57 & 95 days). Regression models revealed that race/ethnicity and recent
inpatient psychiatric treatment were negatively associated with stimulant persis-
tence in the three stimulant classes. Age (13 years) and addition of another psy-
chotropic medication, however, improved persistence significantly in all three
stimulant classes. CONCLUSIONS: Long acting stimulants had comparatively lon-
ger persistence than other stimulant classes. An understanding of demographic
and clinical characteristics that influence treatment continuation can help to im-
prove persistence rates in ADHD.
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PSYCHOTROPIC POLYPHARMACY IN CHILDREN AND ADOLESCENTS WITH
ATTENTION – DEFICIT / HYPERACTIVITY DISORDER
Palli SR1, Aparasu RR2, Chen H2, Sherer JT2
1HealthCore, Inc., Wilmington, DE, USA, 2University of Houston, Houston, TX, USA
OBJECTIVES: To examine the prevalence and time to psychotropic polypharmacy
in children with Attention-Deficit Hyperactivity Disorder (ADHD).METHODS: This
retrospective longitudinal database analysis of medical, pharmacy and eligibility
data was performed on Medicaid enrollees from four states – Texas, New York,
California, and Illinois – during a 3-year period (January 2003 and December 2005).
ADHD patients were identified on the basis of one or more ADHD diagnosis and
stimulant (short-acting [SAS], intermediate-acting [IAS] or long-acting [LAS]) pre-
scription(s). New stimulant users were selected if the index stimulant prescription
was filed between July 1, 2003 and June 30, 2005 with no previous stimulant drug
prescription in the preceding 6months. Additional eligibility criteria included con-
tinuous Medicaid eligibility 180 days pre- and post- index date and no multiple
index stimulant type claims. Psychotropic polypharmacy episode was defined as
30 consecutive days of non-stimulant therapy overlapping with the index stim-
ulant therapy. The time to psychotropic polypharmacywas assessed by calculating
the time from the index stimulant date to the first day of polypharmacy treatment
episode using the Cox proportional Hazards model. RESULTS: Among the 63,362
ADHD patients, 19.95% of SAS users, 24.26% of IAS users and 29.56% of LAS users
received combination pharmacotherapy involving their index stimulant. Median
survival time to psychotropic polypharmacywas found to be 299, 232, and 330 days
in the SAS, IAS and LAS treatment groups respectively. Recent inpatient psychiatric
visit(s) and younger age emerged as the common risk factors predicting index
stimulant and a psychotropic co-prescription. In addition, race/ethnicity and a
comorbidity of tics were also identified as predictors for LAS-related psychotropic
polypharmacy. CONCLUSIONS: Over one in five new stimulant users with ADHD
received a concomitant non-index stimulant prescription within a year of com-
mencing stimulant therapy. Demographic and clinical characteristics seem to play
a key role in psychotropic polypharmacy in children with ADHD.
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UTILIZATION PATTERN AND TREATMENT ADHERENCE WITH MOOD
STABILIZERS AND ATYPICAL ANTIPSYCHOTICS AMONG PEDIATRIC PATIENTS
WITH BIPOLAR DISORDER: A RETROSPECTIVE CLAIMS-BASED STUDY
Mehta S, Patel A, Chen H
University of Houston, Houston, TX, USA
OBJECTIVES: Monotherapy with traditional mood stabilizers or atypical antipsy-
chotics is recommended as the first-line treatment for pediatric bipolar disorder.
This study examined the prescribing patterns of mood stabilizers and atypical
antipsychotics and adherence to these medications in children and adolescents
diagnosed with bipolar disorder. METHODS: 2003-2005 Medicaid Analytic eXtract
data of four states namely California, Illinois, Texas and NewYorkwas used. Study
participants were 6-18 years old, had a diagnosis of bipolar disorder, and had treat-
ment initiation with atypical antipsychotic ormood stabilizermonotherapy after a
6 month window without filling any of these medications. Descriptive statistics
was performed to observe the utilization pattern of monotherapy with mood sta-
bilizers and atypical antipsychotics. Medication possession ratio (MPR) was com-
pared between mood stabilizers and atypical antipsychotics during the 1 year pe-
riod after the treatment initiation. RESULTS: Out of 62,858 patients diagnosed
with bipolar disorder during the study period from 2003-05, there were a total of
14,946 patients who met inclusion criteria and whose treatment was initiated
with mood stabilizer or atypical antipsychotic monotherapy. Prescription of
atypical antipsychotics (73.36%) was predominantly higher than that of mood
stabilizers (26.64%). Among the atypical antipsychotics, the most frequently
prescribedmedication was risperidone (30%) followed by quetiapine (18.2%) and
olanzapine (14.4%). Among themood stabilizers, themost frequently prescribed
medication was oxcarbazepine (9.3%) followed by lithium (7.6% ) MPR for atyp-
ical antipsychotics was 0.82  0.18 and that of mood stabilizers was 0.81  0.19.
Almost 65% of the patients initiated on either of the medications were fully
adherent (MPR1). CONCLUSIONS: After receiving the recent US FDA approval for
the treatment of bipolar disorder in children and adolescents, atypical antipsychot-
ics are prescribed more frequently than traditional mood stabilizers, especially in
context of monotherapy. However, adherence to both the medication classes was
similar.
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RELATIONSHIP BETWEEN ADHERENCE TO ANTIDEPRESSANT TREATMENTS
AND DEPRESSIVE RELAPSE
Jung SY, Shin S, Song H, Park J, Ahn J
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
OBJECTIVES: To compare the impact of various measures of adherence to antide-
pressant (AD) therapy on the estimation of the rate of depressive relapse using
claims database.METHODS: Using the Korean Health Insurance Review & Assess-
ment Service (HIRA) claims database (2006-2008), patients aged 18-84withoutmed-
ical visit due to depression (ICD 10F06.3, F31.3, F31.4, F32, F33, F34.1, F38.1, F41.2)
within 6 months before the first observed prescription of ADs between July 2006 to
Jun 2007 (18 months index period), and with at least 3 psychiatric visits within 3
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